AntionkoRAN-M is under clinical development by Gene Surgery and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AntionkoRAN-M’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AntionkoRAN-M overview

AntionkoRAN-M is under development for the treatment of advanced solid tumors including sarcomas, melanoma, head and neck cancer squamous cell carcinoma, breast cancer, cervical cancer, vulvar cancer, penile cancer, anal cancer. The therapeutic candidate comprises of plasmid DNA that contains the HSVtk killer gene and the cytokine gene GM-CSF enclosed in a polycationic envelope. It is administered by intratumoral route.

For a complete picture of AntionkoRAN-M’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.